EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Efficacy of upadacitinib induction for pediatric inflammatory bowel disease

Evan Greenhall, Nina Gautam, Paula Prieto-Jimenez, Elizabeth Hilow, Ashish Patel, Brad Pasternak iD

JPGN Reports · 2026-05 · 7 (2) · 296-300

DOI: 10.1002/jpr3.70157 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JPGN Reports, online erschienen am 05.03.2026. Verfasst von Evan Greenhall und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Gastroenterology Phoenix Children's Hospital Phoenix Arizona USA. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Upadacitinib, a second‐generation Janus kinase (JAK) inhibitor, is approved for moderate to severe Crohn's disease (CD) and ulcerative colitis (UC) in adults. Its efficacy in pediatric patients remains unclear, though early reports suggest benefits in refractory inflammatory bowel disease (IBD). However, data indicate potential relapse after dose reduction. This study evaluates upadacitinib's sustained efficacy in pediatric IBD, particularly when transitioning from induction to maintenance dosing.

Methods

We conducted a case series of 16 pediatric patients (mean age 16.1 years) treated with upadacitinib for refractory IBD between 2023 and 2024. Treatment responses were analyzed in 8 patients who completed induction (45 mg daily) and transitioned to maintenance dosing (30 or 15 mg daily based on provider preference). Relapse rates and responses to dose adjustments were assessed.

Results

Among the 16 patients, 8 had UC, 7 had CD, and 1 had IBD‐unclassified. Seven (43.8%; 95% confidence interval [CI], 19.4%–68.1%) lost response after transitioning to maintenance, with a median time to relapse of 81.5 days. Of these, 6 (85.7%; 95% CI, 42%–99%) regained response after increasing the dose back to induction dosing.

Conclusion

Our findings suggest that pediatric patients may require longer induction, higher maintenance doses, or individualized dosing due to pharmacokinetics. Given the high relapse rate in our small cohort, close monitoring and tailored treatment strategies are essential.

Schlagwörter

Stichwörter der Autor:innen

Crohn's diseaseJAK inhibitorulcerative colitis

Autor:innen und Institutionen

  • Division of Pediatric Gastroenterology Phoenix Children's Hospital Phoenix Arizona USA.
  • University of Arizona College of Medicine- Phoenix Phoenix Arizona USA.

ORCID-Profile: Brad Pasternak

Zitieren

APA

Greenhall, E., Gautam, N., Prieto-Jimenez, P., Hilow, E., Patel, A., & Pasternak, B. (2026). Efficacy of upadacitinib induction for pediatric inflammatory bowel disease. JPGN Reports, 7(2), 296-300. https://doi.org/10.1002/jpr3.70157

Vancouver

Greenhall E, Gautam N, Prieto-Jimenez P, Hilow E, Patel A, Pasternak B. Efficacy of upadacitinib induction for pediatric inflammatory bowel disease. JPGN Reports. 2026;7(2):296-300. doi:10.1002/jpr3.70157

BibTeX
@article{Greenhall2026,
  author = {Greenhall, Evan and Gautam, Nina and Prieto-Jimenez, Paula and Hilow, Elizabeth and Patel, Ashish and Pasternak, Brad},
  title = {Efficacy of upadacitinib induction for pediatric inflammatory bowel disease},
  journal = {JPGN Reports},
  year = {2026},
  volume = {7},
  number = {2},
  pages = {296--300},
  doi = {10.1002/jpr3.70157}
}
Kostenlos starten →